BioNTech SE
(NASDAQ : BNTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 8.62%147.500.0%$973.92m
AMGNAmgen, Inc. 0.74%254.931.5%$858.31m
GILDGilead Sciences, Inc. -0.19%64.351.0%$543.81m
VRTXVertex Pharmaceuticals, Inc. 1.08%272.571.9%$493.00m
REGNRegeneron Pharmaceuticals, Inc. 0.89%689.532.6%$438.41m
ILMNIllumina, Inc. 4.99%255.723.3%$329.10m
NVAXNovavax, Inc. 18.46%55.7675.7%$306.15m
BIIBBiogen, Inc. 0.35%204.931.8%$233.51m
BNTXBioNTech SE 4.34%165.010.0%$220.14m
SNSSSunesis Pharmaceuticals, Inc. 2.38%2.150.7%$150.29m
EXASEXACT Sciences Corp. 7.03%53.3717.7%$137.22m
TXG10X Genomics, Inc. 13.16%53.580.0%$107.62m
TECHBio-Techne Corp. 5.03%383.704.5%$105.36m
BMRNBioMarin Pharmaceutical, Inc. 2.32%80.694.2%$96.74m
CRSPCRISPR Therapeutics AG 5.02%58.000.6%$84.43m

Company Profile

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.